PGI8 An Exploratory Analysis of the Survival Benefits in Commercially Insured Patients with Hepatic Encephalopathy (HE) Treated with Rifaximin versus Lactulose Alone using US Claims Data
Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.498
https://www.valueinhealthjournal.com/article/S1098-3015(21)00715-4/fulltext
Section Title :
Section Order :
11048
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00715-4&doi=10.1016/j.jval.2021.04.498